Download presentation
Presentation is loading. Please wait.
Published byCoral Bradford Modified over 5 years ago
1
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma by Matthew J. Matasar, Myron S. Czuczman, Maria Alma Rodriguez, Michael Fennessy, Thomas C. Shea, Gary Spitzer, Izidore S. Lossos, Mohamed A. Kharfan-Dabaja, Robin Joyce, Luis Fayad, Kristen Henkel, Qiming Liao, Klaus Edvardsen, Roxanne C. Jewell, Doug Fecteau, Rajendra P. Singh, Steen Lisby, and Craig H. Moskowitz Blood Volume 122(4): July 25, 2013 ©2013 by American Society of Hematology
2
Treatment protocol. Treatment protocol. Routine cycle length was 21 days. *Stem cell mobilization could be performed in cycle 2 and/or cycle 3. FL, follicular lymphoma; Gr3B, grade 3B; O, ofatumumab; PD, progressive disease. Matthew J. Matasar et al. Blood 2013;122: ©2013 by American Society of Hematology
3
CONSORT diagram of distribution of patients according to treatment assignation.
CONSORT diagram of distribution of patients according to treatment assignation. O, ofatumumab. Matthew J. Matasar et al. Blood 2013;122: ©2013 by American Society of Hematology
4
Progression free survival.
Progression free survival. (A) PFS for O-DHAP and O-ICE. Median PFS for O-DHAP was 301 days (95% confidence interval [CI] 152, not estimable); median PFS for O-ICE was 288 days (95% CI 177, not estimable). (B) PFS according to saaIPI, 0 to 1 risk factors vs 2 to 3 risk factors. Median PFS for 0 to 1 risk factors was not reached (95% CI: 288, not estimable), median PFS for 2 to 3 risk factors was 177 days (95% CI 117, 264). (C) PFS according to response to first-line therapy, CR >12 months vs CR ≤ 12 months or failure to achieve remission. Median PFS for CR >12 months was not reached (95% CI 375, not estimable); median PFS for CR ≤ 12 months or failure to achieve remission was 261 days (95% CI 152, 296). O, ofatumumab. Matthew J. Matasar et al. Blood 2013;122: ©2013 by American Society of Hematology
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.